Gardette Mite: Uses, Dosage & Side Effects

What Is Gardette Mite and What Is It Used For?

Gardette mite is a fixed-dose combination inhaler that delivers two complementary active substances simultaneously to the lungs with each inhalation. The first active ingredient, budesonide, is a potent synthetic glucocorticoid (inhaled corticosteroid, ICS) that exerts a powerful local anti-inflammatory effect on the airways. Budesonide works by binding to intracellular glucocorticoid receptors in airway epithelial cells, immune cells, and smooth muscle cells. This binding triggers a cascade of genomic effects: it suppresses the transcription of pro-inflammatory genes encoding cytokines (such as IL-1, IL-4, IL-5, IL-6, IL-8, and TNF-alpha), chemokines, adhesion molecules, and inflammatory enzymes (such as cyclooxygenase-2 and inducible nitric oxide synthase). The result is a reduction in airway inflammation, mucus hypersecretion, edema, and the number and activation of inflammatory cells (eosinophils, T-lymphocytes, mast cells, and macrophages) within the bronchial mucosa.

The second active ingredient, formoterol fumarate dihydrate, is a selective long-acting beta-2 adrenoceptor agonist (LABA). Formoterol works by stimulating beta-2 adrenergic receptors on bronchial smooth muscle cells, which activates the enzyme adenylyl cyclase and increases intracellular concentrations of cyclic adenosine monophosphate (cAMP). Elevated cAMP levels lead to relaxation of bronchial smooth muscle, resulting in bronchodilation and improved airflow. Unlike some other LABAs, formoterol has both a rapid onset of action (within 1–3 minutes, comparable to salbutamol) and a long duration of effect (approximately 12 hours). This unique pharmacological profile allows formoterol-containing combination inhalers to be used as both maintenance and reliever therapy (the MART approach), a strategy endorsed by the Global Initiative for Asthma (GINA) guidelines.

The combination of budesonide and formoterol in a single inhaler offers several clinical advantages over using each component separately. First, it improves treatment adherence because patients need to use only one device instead of two. Poor adherence to inhaled corticosteroids is one of the most common reasons for inadequate asthma control worldwide, and combination inhalers help address this problem by ensuring that patients receive their anti-inflammatory medication every time they use their bronchodilator. Second, the complementary mechanisms of action provide synergistic effects: corticosteroids upregulate the expression of beta-2 adrenergic receptors on airway smooth muscle (preventing the downregulation that can occur with prolonged LABA use), while LABAs enhance the translocation of glucocorticoid receptors to the cell nucleus, potentiating the anti-inflammatory effects of the corticosteroid. Third, the rapid onset of formoterol means that patients experience immediate symptomatic relief alongside the longer-term anti-inflammatory benefits of budesonide.

Gardette mite is indicated for the following conditions:

• Asthma: Regular treatment of asthma in patients where use of a combination product (inhaled corticosteroid and long-acting beta-2 agonist) is appropriate. This includes patients not adequately controlled with inhaled corticosteroids and as-needed short-acting beta-2 agonists alone, or patients already adequately controlled on both an inhaled corticosteroid and a long-acting beta-2 agonist. The “mite” strength (80/4.5 mcg) represents GINA Step 3 treatment and is appropriate for mild-to-moderate persistent asthma.
• COPD (in some jurisdictions): Symptomatic treatment of patients with severe COPD (FEV1 <50% predicted) who have experienced repeated exacerbations despite regular therapy with long-acting bronchodilators.

The “mite” designation in the product name signifies that this is the lowest available strength in the budesonide/formoterol product range. Higher strengths (such as 160/4.5 mcg and 320/9 mcg per inhalation) are available for patients requiring more intensive therapy. The mite strength is particularly suitable as a starting dose for patients with mild-to-moderate asthma, for adolescents and children aged 6 years and older, and for patients who are being stepped down from higher-dose ICS/LABA combinations after achieving adequate disease control.

Clinical evidence supporting budesonide/formoterol combination therapy is extensive. Landmark clinical trials, including the FACET study, COMPASS study, and multiple GINA-endorsed trials, have consistently demonstrated that budesonide/formoterol combination therapy provides superior asthma control compared with the same dose of ICS alone, with significant reductions in exacerbation rates, improvements in lung function (FEV1), reductions in rescue inhaler use, and improvements in patient-reported symptom scores and quality of life. The SMART (Symbicort Maintenance and Reliever Therapy) and subsequent MART studies have further shown that using budesonide/formoterol as both maintenance and reliever therapy reduces the risk of severe asthma exacerbations more effectively than fixed-dose maintenance with a separate rescue inhaler.

What Should You Know Before Taking Gardette Mite?

Contraindications

Gardette mite is contraindicated in patients with known hypersensitivity (allergy) to budesonide, formoterol fumarate dihydrate, or to the excipient inhaled lactose (which contains trace amounts of milk proteins). Although extremely rare, patients with severe milk protein allergy should discuss this with their prescribing physician, as the dry powder formulation uses lactose monohydrate as a carrier substance. If you have ever had a severe allergic reaction to any of these substances, you must not use this medication.

Gardette mite is not indicated for the relief of acute bronchospasm as a sole treatment. While formoterol provides rapid bronchodilation and the inhaler can be used as a reliever in the MART regimen, it must always be combined with regular twice-daily maintenance use in this context. Patients who do not use the MART approach should carry a separate short-acting beta-2 agonist (such as salbutamol/albuterol) for acute symptom relief.

Warnings and Precautions

Before starting Gardette mite, inform your doctor if you have any of the following conditions, as they may require special monitoring or dose adjustments:

• Heart disease: Including coronary artery disease, cardiac arrhythmias (particularly prolonged QTc interval), severe heart failure, hypertrophic obstructive cardiomyopathy, or idiopathic subvalvular aortic stenosis. Formoterol, like all beta-2 agonists, may cause dose-related cardiovascular effects including increases in heart rate, blood pressure changes, and ECG changes (QTc prolongation, ST segment depression, T-wave flattening). These effects are generally not clinically significant at recommended doses but warrant monitoring in patients with pre-existing cardiovascular disease.
• Diabetes mellitus: Inhaled beta-2 agonists can cause transient increases in blood glucose levels. Patients with diabetes should monitor their blood sugar more frequently when starting treatment with Gardette mite. Inhaled corticosteroids at higher doses may also contribute to glucose elevations, although this is less of a concern at the mite (low-dose) strength.
• Thyroid disorders: Particularly untreated thyrotoxicosis (overactive thyroid). Beta-2 agonists may exacerbate symptoms of hyperthyroidism.
• Low potassium (hypokalemia): Beta-2 agonists can cause a dose-related decrease in serum potassium through intracellular redistribution of potassium. This effect is usually transient and clinically insignificant at therapeutic doses but may be potentiated by concomitant treatment with xanthine derivatives (theophylline), systemic corticosteroids, or diuretics. In patients at risk of hypokalemia, serum potassium levels should be monitored.
• Tuberculosis: Active or quiescent pulmonary tuberculosis, or fungal, viral, or bacterial respiratory infections require special consideration. Inhaled corticosteroids do not treat infections and may potentially mask symptoms. Patients with active TB or untreated respiratory infections should have these conditions treated before starting ICS therapy.
• Adrenal function: Long-term use of high doses of inhaled corticosteroids may lead to suppression of the hypothalamic-pituitary-adrenal (HPA) axis. At the mite strength (80 mcg budesonide per inhalation), the risk of clinically significant adrenal suppression is very low. However, patients transferring from oral corticosteroids to inhaled therapy, or those using multiple corticosteroid preparations concurrently, should be monitored for adrenal insufficiency.
• Osteoporosis: Long-term use of inhaled corticosteroids at high doses may reduce bone mineral density. At the mite strength, this risk is minimal. However, patients with existing osteoporosis or risk factors for osteoporosis should discuss this with their doctor.
• Phaeochromocytoma: This adrenal gland tumor may cause dangerous hypertensive responses to beta-2 agonists. Gardette mite should be used with caution in patients with known or suspected phaeochromocytoma.

Pregnancy and Breastfeeding

If you are pregnant, think you may be pregnant, or are planning to become pregnant, discuss this with your doctor before using Gardette mite. Maintaining good asthma control during pregnancy is essential, as uncontrolled asthma poses significant risks to both the mother and the developing baby, including pre-eclampsia, premature birth, low birth weight, and neonatal complications. The risks of poorly controlled asthma during pregnancy generally outweigh the potential risks of inhaled corticosteroid and LABA treatment.

Budesonide is the most extensively studied inhaled corticosteroid during pregnancy. Large-scale observational studies and pregnancy registries involving thousands of women exposed to inhaled budesonide during pregnancy have not demonstrated an increased risk of congenital malformations or adverse pregnancy outcomes. Consequently, budesonide is considered the preferred ICS for use during pregnancy by most international guidelines, including GINA and the BTS/SIGN guidelines. There is less specific data for formoterol use during pregnancy, but animal studies have not revealed teratogenic effects at clinically relevant doses. The general consensus among respiratory specialists is that maintaining good asthma control with an ICS/LABA combination during pregnancy is preferable to poorly controlled asthma.

Budesonide is excreted in breast milk in small amounts. At therapeutic inhaled doses, the amount reaching the infant through breast milk is expected to be negligible and unlikely to cause any adverse effects. Formoterol is not known to be excreted in human breast milk in significant quantities. Both GINA and the BTS/SIGN guidelines support continued use of inhaled budesonide/formoterol during breastfeeding. Discuss with your doctor, but in most cases the benefits of continued asthma treatment and breastfeeding outweigh the theoretical risks.

Children and Adolescents

Gardette mite (80/4.5 mcg) may be used in children aged 6 years and older for asthma management when a combination ICS/LABA product is considered appropriate. The mite strength is the lowest available dose and is the most commonly prescribed starting strength for pediatric patients. Children under 6 years of age should not use this formulation, as the evidence base and appropriate dosing have not been established in this younger age group. For children requiring only an inhaled corticosteroid, lower-dose budesonide monotherapy via nebulizer or other appropriate delivery device may be more suitable.

Growth should be monitored regularly in children and adolescents receiving prolonged inhaled corticosteroid therapy. Although studies of inhaled budesonide at low-to-moderate doses have shown minimal effect on final adult height (a mean reduction of approximately 1 cm), the benefit of optimal asthma control far outweighs this small effect. The treating physician should aim to use the lowest effective dose that maintains good asthma control.

Driving and Operating Machinery

Gardette mite is not expected to impair the ability to drive or operate machinery. Neither budesonide nor formoterol at inhaled therapeutic doses have been shown to cause sedation, drowsiness, or impairment of cognitive or motor function. However, if you experience any side effects that could affect your alertness or coordination, refrain from driving or operating machinery until these effects have resolved.

How Does Gardette Mite Interact with Other Drugs?

Gardette mite contains two active substances, each with its own pharmacological interaction profile. Budesonide is metabolized primarily by the hepatic cytochrome P450 enzyme CYP3A4, making it susceptible to pharmacokinetic interactions with drugs that inhibit or induce this enzyme. Formoterol, as a beta-2 agonist, has pharmacodynamic interactions with drugs that affect the sympathetic nervous system, cardiac conduction, or electrolyte balance. Understanding these interactions is important for safe and effective use of the medication.

The following table summarizes the most clinically significant drug interactions with Gardette mite:

Other Interactions of Note

Moderate CYP3A4 inhibitors such as erythromycin, clarithromycin, diltiazem, verapamil, and grapefruit juice may moderately increase budesonide plasma levels (approximately 2–3 fold). While less pronounced than with potent inhibitors, concurrent use should be approached with awareness, and patients should be monitored for signs of increased corticosteroid effects if long-term co-administration is necessary.

CYP3A4 inducers such as rifampicin, carbamazepine, phenytoin, and phenobarbital can accelerate budesonide metabolism, potentially reducing its efficacy. Patients using these medications concurrently may require a higher ICS dose or more frequent monitoring of asthma control.

Formoterol can generally be used safely alongside other common asthma and allergy medications, including leukotriene receptor antagonists (montelukast), antihistamines, nasal corticosteroids, and short-acting beta-2 agonists (salbutamol/albuterol) used for acute symptom relief. No clinically significant interactions have been identified with these drug classes.

What Is the Correct Dosage of Gardette Mite?

Gardette mite should always be used exactly as prescribed by your doctor. The dosage is individualized based on disease severity, current level of asthma control, and whether the MART approach is being used. Your doctor will prescribe the lowest effective dose that maintains good asthma control and will review your treatment regularly to ensure it remains appropriate.

Adults (18 years and older)

When used as fixed-dose maintenance therapy, the standard adult dose is 1 to 2 inhalations twice daily (morning and evening). Most patients achieve good asthma control with 2 inhalations twice daily (total daily dose: budesonide 320 mcg + formoterol 18 mcg). In some patients whose asthma is well controlled, the dose may be reduced to 1 inhalation twice daily. A separate rapid-acting bronchodilator (short-acting beta-2 agonist such as salbutamol) should be prescribed for acute symptom relief.

When used as maintenance and reliever therapy (MART), the regular maintenance dose is 1 inhalation twice daily. In addition, patients take 1 extra inhalation as needed in response to symptoms. If symptoms persist after a few minutes, an additional inhalation may be taken. On any single occasion, no more than 6 additional inhalations should be taken. The total maximum number of inhalations per day should not normally exceed 8. Patients who frequently need the maximum number of reliever inhalations should be reviewed by their doctor, as this may indicate that the maintenance dose is insufficient and the treatment regimen needs to be adjusted.

Children and Adolescents (6–17 years)

Elderly Patients

No specific dose adjustment is required for elderly patients. The dosing recommendations are the same as for younger adults. However, elderly patients may be more susceptible to certain side effects, including oral candidiasis and systemic effects of corticosteroids (such as bone density reduction and bruising). They may also have concurrent cardiovascular conditions that warrant caution with the beta-2 agonist component. Regular clinical review is advisable.

Missed Dose

If you forget to take a scheduled dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to compensate for a forgotten dose. Consistent use of the maintenance dose is important for optimal disease control. Setting a daily reminder (alarm, phone reminder, or placing the inhaler next to your toothbrush) can help maintain adherence.

Overdose

An overdose of formoterol may result in tremor, headache, palpitations, tachycardia, nausea, and hyperglycemia. The most commonly reported effects of formoterol overdose are those typical of beta-2 agonist excess: muscle tremor, tachycardia, hypokalemia, and hyperglycemia. An overdose of budesonide, even at substantially higher inhaled doses, is unlikely to cause acute clinical problems. However, chronic overdose of inhaled budesonide may lead to systemic corticosteroid effects, including adrenal suppression, reduced growth velocity in children, reduced bone mineral density, cataracts, glaucoma, and Cushingoid features.

If you suspect an overdose, contact your doctor or local poison control center. There is no specific antidote. Treatment is supportive, with monitoring of cardiac rhythm and serum potassium. In severe formoterol overdose, cardioselective beta-blocker therapy may be considered, but only with extreme caution due to the risk of bronchospasm.

How to Use the Dry Powder Inhaler

Correct inhaler technique is essential for effective drug delivery to the lungs. A significant proportion of patients with asthma and COPD use their inhalers incorrectly, leading to poor drug deposition in the lungs and suboptimal disease control. Follow these steps carefully:

1. Open: Hold the inhaler upright (mouthpiece pointing up). Twist the base (colored grip) to open the inhaler, exposing the mouthpiece.
2. Load: Hold the inhaler upright. Twist the grip fully in one direction, then twist it fully back in the other direction until you hear a “click.” This loads a single dose. Do not shake the inhaler after loading. Do not breathe into the mouthpiece.
3. Exhale: Breathe out gently, away from the inhaler. Do not exhale into the mouthpiece, as moisture from your breath can affect the powder.
4. Inhale: Place the mouthpiece between your teeth and close your lips around it to form a seal. Inhale deeply and forcefully through the mouth (not through the nose). The powder has no strong taste, so you may not feel or taste the dose.
5. Hold: Remove the inhaler from your mouth and hold your breath for approximately 5–10 seconds, or as long as comfortably possible. This allows the medication to settle in the airways.
6. Repeat: If a second inhalation is prescribed, repeat steps 2–5.
7. Rinse: After your last inhalation, rinse your mouth thoroughly with water and spit it out. This reduces the risk of oral candidiasis and hoarseness.
8. Close: Twist the grip back to close the mouthpiece.

What Are the Side Effects of Gardette Mite?

Like all medicines, Gardette mite can cause side effects, although not everyone who uses it will experience them. The side effects are primarily related to the individual pharmacological actions of each active ingredient: budesonide (an inhaled corticosteroid) and formoterol (a long-acting beta-2 agonist). Most side effects are mild, dose-related, and tend to diminish with continued use as the body adjusts to the medication.

The safety profile of budesonide/formoterol combination inhalers has been extensively studied in clinical trials involving tens of thousands of patients, as well as in post-marketing surveillance spanning more than two decades of clinical use. The mite strength (80/4.5 mcg) delivers the lowest dose of both components, and therefore carries the lowest risk of dose-dependent side effects within the product range.

Oral candidiasis (thrush) is the most frequently reported side effect of inhaled corticosteroids. It results from local immunosuppression in the oropharynx, where deposited budesonide particles suppress local mucosal immunity and allow overgrowth of Candida albicans. The risk is directly related to the ICS dose, the frequency of inhalation, and whether or not the patient rinses their mouth after use. At the mite strength, the risk is lower than with higher-dose formulations, and consistent mouth rinsing reduces the incidence by approximately 50–70%. If oral candidiasis develops, it is typically mild and responds well to topical antifungal treatment (such as nystatin or miconazole oral gel) without the need to discontinue the inhaler.

Hoarseness (dysphonia) affects approximately 5–10% of patients using inhaled corticosteroids and results from the local effect of budesonide on the laryngeal muscles. It is usually mild and reversible. Strategies to minimize dysphonia include using a spacer device (if compatible with the inhaler), rinsing the mouth after use, and ensuring correct inhaler technique to minimize oropharyngeal drug deposition.

Tremor and palpitations are related to the beta-2 agonist component (formoterol) and are more common at the start of treatment. These effects are dose-dependent and usually mild and transient, subsiding within the first 1–2 weeks of regular use as tolerance develops to the peripheral beta-2 stimulant effects. If tremor or palpitations are persistent or troublesome, consult your doctor.

Paradoxical bronchospasm is a rare but potentially serious reaction where the airways constrict immediately after inhalation, causing sudden worsening of breathing. If this occurs, stop using the inhaler, use your rescue bronchodilator (salbutamol), and contact your doctor. An alternative inhaler formulation or device may be needed.

How Should You Store Gardette Mite?

Proper storage is important to ensure the medication retains its full potency and the dry powder remains free-flowing for effective delivery to the lungs. The inhalation powder is sensitive to moisture, which can cause the powder to clump and reduce the delivered dose.

• Temperature: Store below 30 °C (86 °F). Do not expose to extreme heat or cold. Do not freeze.
• Moisture protection: Keep the cover (mouthpiece cap) tightly closed when the inhaler is not in use. Do not store in the bathroom, as humidity can affect the dry powder. Do not breathe into the inhaler after loading a dose.
• In-use shelf life: Use within 3 months of first opening the inhaler, even if there are doses remaining. Mark the date of first opening on the inhaler packaging for reference.
• Expiry date: Do not use after the expiry date printed on the packaging and inhaler label. The expiry date refers to the last day of that month.
• Keep out of reach of children: Store the inhaler in a safe place where children cannot access it.
• Dose counter: The inhaler may have a dose counter or indicator window. When the counter reaches zero or the indicator shows red, the inhaler is empty and should be replaced with a new one, even if it feels like there is powder remaining.
• Disposal: Do not dispose of inhalers in household waste. Return used or expired inhalers to your pharmacy for proper disposal according to local environmental regulations.

When traveling, keep the inhaler in your hand luggage (not in checked baggage, which may be exposed to extreme temperatures in the cargo hold). There are no restrictions on carrying prescription inhalers through airport security, but it is advisable to keep the medication in its original packaging with the prescription label visible.

What Does Gardette Mite Contain?

Understanding the composition of your medication is important, particularly if you have known allergies or dietary restrictions. Gardette mite has a simple formulation with only two active ingredients and one excipient.

Active Ingredients

Budesonide is a synthetic glucocorticoid with high topical (local) anti-inflammatory potency and low systemic bioavailability when inhaled. It has a high affinity for the glucocorticoid receptor and undergoes extensive first-pass metabolism in the liver (approximately 90%), which means that only a small fraction of the inhaled dose reaches the systemic circulation. This favorable pharmacokinetic profile gives budesonide an excellent ratio of local anti-inflammatory effect to systemic side effects.

Formoterol fumarate dihydrate is a selective, long-acting beta-2 adrenoceptor agonist with a uniquely rapid onset of action. It has a lipophilic side chain that anchors it near the beta-2 receptor in the cell membrane, providing a sustained bronchodilatory effect lasting approximately 12 hours. Formoterol relaxes bronchial smooth muscle, increases mucociliary clearance, reduces microvascular leakage, and inhibits the release of mediators from mast cells and basophils.

Lactose monohydrate is a naturally occurring sugar derived from cow’s milk that is used as a carrier to improve the flow properties of the dry powder and to facilitate accurate dosing. The amount of lactose in each inhalation is very small and is well tolerated by the vast majority of patients, including those with lactose intolerance (since lactose intolerance involves digestive enzymes, and the inhaled amount is negligible). However, patients with a severe allergy to milk proteins should consult their doctor before using this product, as trace milk proteins are present in the lactose.

Appearance and Pack Sizes

Gardette mite is supplied as a white to off-white dry powder in a multi-dose dry powder inhaler device. The inhaler typically contains 60 or 120 metered doses, depending on the pack size available in your country. The device has a built-in dose counter that shows the approximate number of doses remaining. Not all pack sizes may be marketed in every country.